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Hyperbolic relation between beta-cell function and insulin sensitivity for type 2 diabetes
mellitus, malaria, influenza, Helicobacter pylori, Chlamydia pneumoniae,
and hepatitis C virus infection-induced inflammation/oxidative stress and temporary
insulin resistance in Central Africans*
1

1,2,3

Jean Bosco Kasiam Lasi ON’KIN , Benjamin LONGO-MBENZA ,
4,
3
3
Venant TCHOKONTE-NANA *, Augustin Nge OKWE , Nelly Kangola KABANGU
1
Department of Internal Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
2
University of President Kasa Vubu, Boma, Democratic Republic of the Congo
3
Biostatistics Unit, LOMO Medical Center and Heart of Africa Center of Cardiology, Kinshasa, Democratic Republic of the Congo
4
Islet & MSK Research Group, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
Received: 09.08.2016

Accepted/Published Online: 12.09.2017

Final Version: 19.12.2017

Background/aim: We calculated the homeostatic model assessment (HOMA) for estimating insulin sensitivity and beta-cell function
in normal, healthy nondiabetics with infections (malaria, influenza, HIV, Helicobacter pylori, Chlamydia pneumoniae, and hepatitis C
virus), type 2 diabetic black patients, and healthy controls from Kinshasa, DR Congo.
Materials and methods: A case-control study was carried out between 2006 and 2007 for black Central African participants managed
for HOMA.
Results: In total, 219 patients and 110 healthy controls were matched for sex and age. The hyperbolic product for 85 infected patients
occupied an intermediate position between the hyperbolic product for 110 controls and that of 134 type 2 diabetics. Inflammation/
oxidative stress was present in all infected patients, as well as in the type 2 diabetics. Of the patients, 39.3% and 49.8% had insulin
resistance and metabolic syndrome, respectively. Insulin resistance was more prevalent in nondiabetics with inflammation/oxidative
stress (47.1%; P = 0.041) than in type 2 diabetics (34.3%). Type 2 diabetics had higher insulin sensitivity and lower beta-cell function
but a similar HOMA-IR score.
Conclusion: We recommend the assessment of insulin resistance in Central African patients with severe infections and type 2 diabetes.
Key words: Insulin resistance, type 2 diabetes, inflammation, sub-Saharan Africa, homeostatic model assessment

1. Introduction
Homeostasis model assessment (HOMA) is well
established as a reliable surrogate and mirror of the
glucose clamp technique in the diagnosis of insulin
sensitivity (1). The hyperbolic function qualitatively
defines the interrelationship between insulin resistance
and beta-cell secretion (2–9), while the disposition index
quantitatively derives from the nonlinear hyperbola-like
curve with an integrated figure of glucose tolerance that
includes both insulin sensitivity and secretion (10). Insulin
resistance is defined as a state of a cell, tissue, or organism
in which it is required to elucidate a quantitatively normal
response (11). It can also be the state in which a subnormal
glucose-lowering response is observed in the setting of a
known concentration of insulin (12–17). Consequently,
* Correspondence: venant.tnana@gmail.com

1834

hyperinsulinemia is not a part of the individual components
in which abdominal obesity and innate immunity play key
roles in the development of insulin resistance, chronic
inflammation, and metabolic syndrome elements through
the effects of adipokines (leptin, adiponectin, and resistin)
and cytokines (tumor necrosis factor-α, interleukin-6) in
liver, skeletal muscle, and immune cells (18).
Clinical and epidemiological data show that
inflammatory factors and insulin resistance may be
associated with obesity, important risk factors of insulin
resistance (7,19,20), type 2 diabetes mellitus (21), and
acute phase reactants (22). In this sense, the burden of
infection (enteroviruses and Chlamydia pneumoniae) and
their treatment are associated with chronic low-grade
inflammation and oxidative stress, resulting in insulin
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resistance and atherosclerosis (23,24). Interestingly,
data from sub-Saharan Africa (25–31) also report a
significant association between higher cardiometabolic
risk (dyslipidemia, arterial hypertension, type 2 diabetes
mellitus, stroke, coronary heart disease, and metabolic
syndrome) and infections (HIV, Helicobacter pylori
infection, malaria, and bacterial pneumonia). This
condition may explain the emergence of atherosclerosis
(stroke and myocardial infarction) and type 2 diabetes
mellitus in sub-Saharan African populations (26,29,32–
37).
Neither the Democratic Republic of the Congo (DRC)
nor the Central African region has published data to
show the critical importance of beta-cell dysfunction for
the development of type 2 diabetes mellitus and selected
infections. Therefore, the primary objective of this study
was to investigate whether insulin secretion and insulin
sensitivity are correlated with an inverse, nonlinear
function at different positions in Bantu Central Africans
with type 2 diabetes mellitus, in a group of patients with
infections (malaria, influenza, HIV, Helicobacter pylori,
Chlamydia pneumoniae, and hepatitis C), and in some
healthy controls. The secondary objective of the study
was to compare metabolic syndrome, pancreatic function,
inflammatory, and oxidative stress markers between the
type 2 diabetes mellitus and infection groups.
2. Materials and methods
2.1. Study design, period, and setting
This case-control and comparative study was carried out
over a period of 21 months between 2006 and 2007 at the
Kinshasa University Teaching Hospital, Kinshasa, DRC.
The study protocol was designed according to the Helsinki
Declaration II and approved by the local ethics committee.
2.2. Participants
Two kinds of participants were eligible: first, newly onset
type 2 diabetes mellitus and infected patients admitted
to the Emergency Unit of the Department of Internal
Medicine, and, second, blood donors for family patients
hospitalized within the same study period and setting.
These two groups were eligible to be considered using
structured and standardized questionnaires, a physical
examination, and laboratory analysis after a 12-h overnight
fast.
2.3. Inclusion and exclusion criteria
Out of those eligible participants, black Bantu adults
(≥20 years of age) were included in this study and were
examined by trained physicians and specialists after the
participants had given their informed consent.
Eligible participants and controls who were excluded
were those with a history of smoking, excessive alcohol
intake, dysfunctional thyroid, nephrotic syndrome,

pregnancy, polycystic ovarian syndrome in women, and
diabetes mellitus treatment.
2.4. Data collection
Demographic data (sex and age), behavior (smoking
and alcohol intake), weight, height, waist circumference,
inflammation and oxidative stress markers, lipid profile,
fasting blood glucose, uremia, blood pressure, insulin
sensitivity, and beta-cell secretion were recorded. Body
weight, height, blood pressure, and waist circumference
were measured by standard methods for participants
wearing light clothes and without shoes as described
elsewhere (34).
Glucose levels were measured in fasting plasma
samples using the glucose-oxidase method and
spectrophotometer (Hospitex Diagnostics, Florence,
Italy). Total cholesterol, HDL-cholesterol, uric acid, and
triglycerides were measured using enzymatic colorimetric
methods (BioMérieux, Marcy l’Etoile, France) at the
central Laboratory of LOMO Medical Center, Kinshasa,
DRC. Antibodies against oxidized LDL-cholesterol
were measured using a solid-phase two-site enzyme
immunoassay based on the direct sandwich technique, in
which there are two genetic determinants on the oxidized
apolipoproteins B molecule (Mercodia AB, Uppsala,
Sweden).
Helicobacter pylori infection was assayed by the
determination of IgG antibodies as described elsewhere
(38). Serum was tested for specific IgG class antibodies
against C. pneumoniae through the use of quantitative
in vitro enzyme-linked immunosorbent assays (ELISAs)
based on broad-reactive chlamydial inclusions (IgG)
(Novagnost Test Kit 96x1, Dade Bahring Marburg
GmbH, Marburg, Germany). Serum C-reactive protein
(CRP) (Beckman, Fullerton, CA, USA) was determined
by a routine laboratory test with intra- and interassay
coefficients of variation of <3%. HIV RNA viral load
(Nuclisens Easy Q HIV-1, BioMérieux, Boxtel, the
Netherlands) were recorded for HIV infection. Malaria
and influenza were determined using standard routine
techniques. Hepatitis C virus seropositivity was assayed
using a Hexagon HCV immunochromatographic rapid
test for IgG antibodies against hepatitis virus C (Human,
Wiesbaden, Germany).
For each fasting participant, the plasma insulin level
was assayed in the same laboratory by an ELISA method
using Mercodia kits (Mercodia AB, Uppsala, Sweden).
Glycosylated hemoglobin (HbA1c) was measured in
fresh blood samples with both migration (HYDRASYS
System, Sebia, Lisses, France) and densitometry scanning
of unstained gels (HYDRAGEL 7Ms Hb1C on a HYRYS
densitometer). Plasma C-peptide levels were analyzed
using a solid-phase two-site enzyme immunoassay
quantitative method (ELISA) (Mercodia AB, Uppsala,
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Sweden). The blood determinations performed in the
LOMO Medical Center laboratory were documented to be
valid and reliable following internal and external quality
control.
2.5. Definitions
Type 2 diabetes mellitus was defined according to an expert
committee on the diagnosis and classification of diabetes
mellitus (14). The homeostatic assessment model for
insulin resistance (HOMA-IR) was calculated as follows:
fasting plasma glucose (mmol/L) × fasting plasma insulin
(µU/mL)/22.5, as described by Matthews et al. (39). Using
this method, high HOMA scores of ≥2.5 denoted low
insulin sensitivity (insulin resistance: IR-HOMA). Insulin
sensitivity (S% = 1/[HOMA-IR]), beta-cell function for
insulin secretion (beta% = [20 × insulin]/[(fasting glucose:
18) – 3.5]), quantitative insulin sensitivity check index
(QUICKI = 1/[log fasting glucose + log insulin), and
reciprocal index of HOMA (RECIHOMA = 405/[fasting
glucose × fasting insulin]) were calculated (40). Oxidative
stress was defined by antibodies against oxidized LDLcholesterol levels of ≥60 U/L.
2.6. Statistical analysis
Descriptive results of continuous variables were expressed
as means ± SD, while those of categorical variables were
expressed as proportions (%). Before statistical analysis for
continuous variables was conducted, normal distribution
and homogeneity of the variances were evaluated using
Levene’s test.
Differences between groups (type 2 diabetics vs.
nondiabetics with inflammation/oxidative stress) were
tested with the chi-square test for categorical variables and
ANOVA for continuous variables. In this patient-study

population (type 2 diabetics + nondiabetics with infectioninduced inflammation/oxidative stress status), the relation
between variables was tested using simple linear regression.
Graphic representations of the hyperbolic relation between
beta-cell function and insulin sensitivity were plotted
for type 2 diabetics, nondiabetics with inflammation/
oxidative stress, and healthy participants with normal
glucose tolerance in the same scale of values (<200% betacell function and <300% insulin sensitivity), respectively.
This was done to demonstrate the intermediate position
of inflammation/oxidative stress between normal glucose
tolerance and type 2 diabetes.
Because of the drastic loss of insulin sensitivity for
certain type 2 diabetics and the lack of normally distributed
insulin sensitivity and beta-cell function in the patientstudy population, additional graphs of hyperbolic product
between QUICKI and RECIHOMA were plotted for type
2 diabetics and nondiabetics with inflammation/oxidative
stress, respectively. This was performed to denote their
respective departure from the normal curve and the higher
rate of insulin resistance due to inflammation. P < 0.05 was
considered statistically significant. All computations were
carried out with SPSS 13 for Windows (Chicago, IL, USA).
3. Results
In total, 219 patients (120 men, 99 women; aged 15 to 42
years) and 110 controls (55 men, 55 women; aged 14 to 42
years) were evaluated. The hyperbolic product for infected
patients occupied an intermediate position between the
hyperbolic product for controls with normal glucose
tolerance and that of type 2 diabetics (Figure 1).
Among the 219 patients, the frequency of insulin
resistance was estimated at 39.3%. Insulin resistance was
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Figure 1. Hyperbolic relation between beta-cell function and insulin sensitivity for type
2 diabetics (red color), infected and nondiabetic patients (green color), and controls
(blue color).
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present more often among infected patients than in type
2 diabetics. However, inflammatory-induced oxidative
stress was present in all infected patients (100%), as well as
in type 2 diabetic patients (100%).
Table 1 summarizes the general characteristics
between the type 2 diabetes mellitus and infection groups.
Compared to the infected patients, type 2 diabetics had
a higher waist circumference, lower insulinemia, higher
fasting glucose, lower C-peptide, higher HbA1c, higher
insulin sensitivity, and lower beta-cell function; however,
they had similar HOMA-IR scores (Table 1), as well as a
similar manner of departing from normal glucose tolerance
by the same hyperbolic relation between RECIHOMA and
QUICKI (Figure 2).
In all patients, the frequency of metabolic syndrome as
defined by the International Diabetes Federation criteria
was estimated at 49.8%. The frequency of insulin resistance
in patients with metabolic syndrome was similar (P =
0.438) to that of patients without metabolic syndrome.
However, there was a significant association between
metabolic syndrome and type 2 diabetes. Thus, 66.4% of
type 2 diabetics had metabolic syndrome as opposed to
23.5% of infected patients.
In each group of patients, the influence of sex (Figure 3)
and that of abdominal obesity (Figure 4) on the hyperbolic
relation between RECIHOMA and QUICKI was neutral,
respectively.
Table 2 shows the correlation between insulin
metabolism with age, waist circumference, fasting blood
glucose, HbA1c, and C-peptide in each group of patients.
In type 2 diabetics, there was no significant association
between age, waist circumference, HbA1c, and insulin
metabolism versus a significant negative association
between insulin sensitivity, beta-cell function, and fasting
blood glucose. In infected patients, the only significant

negative association was observed between insulin
sensitivity, beta-cell function, and fasting blood glucose.
The loss of beta-cell function with increasing blood glucose
levels was paradoxically higher in infected patients (r =
–0.757, P < 0.0001) than in type 2 diabetics (r = –0.592, P
< 0.0001). However, the decrease of insulin sensitivity was
enhanced more by an increase in blood glucose in type 2
diabetics (r = –0.418, P < 0.0001) than in infected patients
(r = –0.309, P < 0.0001).
4. Discussion
The present findings confirmed the hyperbolic relationship
(5–7,9) between insulin sensitivity and beta-cell function
in each group mentioned in the study. Furthermore,
type 2 diabetics and infected patients with temporary
inflammation/oxidative stress depart from the normal
hyperbolic product in healthy individuals with normal
glucose tolerance (2–4,7). In the same scale, excluding
individuals with insulin resistance, nondiabetic patients
with infection-induced inflammation/oxidative stress
occupied an intermediate position between the hyperbolic
product for normal glucose tolerance and that for type
2 diabetes. Strangely enough, the same intermediate
position between normal glucose tolerance and type 2
diabetes is occupied by patients with impaired glucose
tolerance (5). The reverse applies in healthy participants
who had normal blood pressure, waist circumference,
inflammation/oxidative stress markers, and lipid profiles.
A healthy lifestyle (lack of both smoking and alcohol
intake, as well as physical activity), high aerobic capacity,
and elevated absolute skeletal muscle mass render those
healthy participants insulin-sensitive.
This study was also a report on the frequency of
insulin resistance using the HOMA model and metabolic
syndrome in Central African patients with type 2 diabetes

Table 1. Descriptive characteristics in patients study population.
Variables

Pooled,
n = 219

Type 2DM,
n = 134

Infection,
n = 85

P-value

Waist circumference (cm)

85 ± 16

92 ± 11

74 ± 17

<0.0001

Fasting glucose (mg/dL)

182.5 ± 126.4

247 ± 123

81 ± 16

<0.0001

Insulin (µU/mL)

7.9 ± 6.6

4.4 ± 4.5

13.3 ± 5.7

<0.0001

HbA1c (%)

7 ± 3.2

8.5 ± 3.1

4.8 ± 1.6

<0.0001

C-peptide (pmol/mL)

0.8 ± 0.5

0.7 ± 0.4

1.1 ± 0.6

<0.0001

HOMA-IR (score)

2.7 ± 3.5

2.7 ± 1.3

2.7 ± 1.3

0.975

82.1 ± 78.9

59.6 ± 77.8

0.040

12.9 ± 17.2

338.6 ± 351.6

<0.0001

0.8 ± 0.8

0.5 ± 0.4

0.004

6.6 ± 0.9

6.8 ± 0.6

0.017

Insulin sensitivity (%)
Beta-cell function (%)

125.4 ± 234.5

RECIHOMA (index)
QUICKI (index)

6.7 ± 0.8
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Figure 2. Hyperbolic relation between RECIHOMA and
QUICKI in type 2 diabetics and nondiabetics with inflammation/
oxidative stress.

and infection. The proportions of metabolic syndrome and
insulin resistance in these patients were at epidemic levels
and higher than those reported for general Central African
populations (0%–11%) (36,41); meanwhile, a rate of 26%
was reported for developed or emerging countries (42,43).
Insulin resistance was more frequent in the group with
infection than in the group with type 2 diabetes. A low
level of physical activity and a low number and increase
in cytokines for nondiabetics with infections may explain
the higher rate of insulin resistance among nondiabetics
with infections. There was no significant association

6.00

between insulin resistance and metabolic syndrome in
the pooled data of all patients. However, almost 37% of
patients with metabolic syndrome had insulin resistance
and 42% of patients without metabolic syndrome had
insulin resistance. Physical inactivity and heterogeneity in
these patients may explain the lack of association between
insulin resistance and metabolic syndrome in all patients.
In addition, metabolic syndrome was present in 66.4%
of type 2 diabetics but in 23.5% of nondiabetics with
infection. Therefore, the presence of metabolic syndrome
in these black Central African patients multiplied the risk
of type 2 diabetes six times. These findings confirmed that
metabolic syndrome is highly associated with diabetes, as
reported in the Framingham study (44). The findings also
highlight the role of inflammation in insulin resistance.
4.1. Abdominal obesity, metabolic syndrome, age, and
insulin resistance: pathogenesis
In these Central African patients, there was no significant
association between sex, age, abdominal obesity, metabolic
syndrome, and the presence of insulin resistance. This may
be explained by the similar fat mass and girth for men and
women in sub-Saharan populations (45).
4.2. Hyperbolic relation between insulin sensitivity and
beta-cell function
The assessment of insulin sensitivity has become a
frequent need for clinical researchers as insulin resistance
is identified as one of the significant risk factors of type 2
diabetes (44) and atherosclerosis (21).
The HOMA hyperbolic product (insulin sensitivity ×
beta-cell function) reflected the true underlying beta-cell
function adjusted for individual insulin sensitivity (5). In
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Figure 3. Hyperbolic relation between RECIHOMA index and QUICKI by sex in type 2 diabetics (a) and nondiabetics with
inflammation/oxidative stress (b).
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Figure 4. Hyperbolic relation between RECIHOMA index and QUICKI by abdominal obesity presence in type 2
diabetics (a) and nondiabetics with inflammation/oxidative stress (b).
Table 2. Correlation coefficients between insulin metabolism with cardiovascular risk factors in each group of patients.
Age
(years)

WC
(cm)

Glucose
(mg/dL)

HbA1c
(%)

C-peptide
(pmol/mL)

–0.094

–0.163

–0.013

0.164

0.163

In type 2 diabetics
Insulin (µU/mL)
Insulin sensitivity (%)

0.077

0.061

–0.418***

–0.156

Beta cell function (%)

–0.054

–0.135

–0.592***

0.124

–0.064

0.074

0.013

–0.112

–0.208*
0.159

In nondiabetics with inflammation/oxidative stress
Insulin (µU/mL)

–0.208

Insulin sensitivity (%)

0.206

0.094

–0.309**

0.070

0.133

Beta cell function (%)

0.039

0.023

–0.757***

–0.172

–0.050

WC: Waist circumference; *: P < 0.05; **: P < 0.01; ***: P < 0.001.

type 2 diabetics, the HOMA hyperbolic product underlies
the need for successive exogenous insulin treatment (21). In
these Central African patients, the hyperbolic product was
significantly higher in infected nondiabetics than in type
2 diabetics, with or without metabolic syndrome. The true
residual beta-cell function in these Central African type 2
diabetics showed accelerated deterioration compared with
Caucasians (21). This more rapid deterioration hypothesis
may be easily explained by the higher levels of fasting
blood glucose and HbA1c observed in this study.
4.3. Clinical implications
Regardless of the diagnostic criteria used, there is complete
agreement that a therapeutic lifestyle change, with an
emphasis on weight loss and physical activity, constitutes
the first-line therapy for metabolic syndrome and insulin
resistance. Moreover, antibiotic treatment to directly
destroy Helicobacter pylori has significantly prevented

metabolic syndrome/insulin resistance in Central African
patients (38). Metformin, TZDs, statins, and fibrates may
be used to reduce the insulin resistance and metabolic
syndrome effects. The pleiotropic effect of statins may
control the inflammatory/oxidative stress status.
4.4. Limitations
This was a cross-sectional study that established
association but not causality. Certain biases could tend
to underestimate the observed prevalence of insulin
resistance and metabolic syndrome, respectively. For
example, the fact that insulin resistance might cause
increased susceptibility to infection cannot be excluded.
Further investigations to determine whether antibody
scores represent reinfection, reactivation, persistence, or
nonspecific immune stimulation are required.
It was not possible to determine whether malnutrition,
physical activity, or environmental factors deleterious for
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beta-cell function and smoking (exclusion criteria) may hint
at insulin resistance in nondiabetics with inflammation and
type 2 diabetes. It is known that these factors are responsible
for immunodepression and earlier onset of hyperglycemia
in younger and leaner patients. The present cross-sectional
design was also unable to incriminate any genetic (younger
age or genes) or environmental (malaria, HIV, Helicobacter
pylori, steatosis, diet, or glucolipotoxicity) factors that
are responsible for the steeper slope of beta-cell function
in these type 2 diabetics and lower insulin sensitivity in
older, nondiabetic Central Africans than in northern
Caucasian type 2 diabetics (37). Genetics might be more
related to this accelerated deterioration of true residual
beta-cell function (hyperbolic product beta secretion ×
insulin sensitivity) in these native Central Africans, as
was reported in Central African type 2 diabetics living in
Belgium, who had an earlier onset of diabetes mellitus,
concurrent insulin resistance, and earlier loss of insulin
than Belgian Caucasian type 2 diabetics (32).

4.5. Conclusions
In the subjects of this study, the proportions of insulin
resistance and metabolic syndrome are unexpectedly
higher in Central African type 2 diabetics and infected
nondiabetics with inflammation than in the general
population. Clearly, metabolic syndrome was associated
with type 2 diabetes, whereas abdominal obesity, sex, age,
metabolic syndrome, C-peptide, and HbA1c were not
associated with insulin resistance in type 2 diabetics, as
well as in infected nondiabetics with inflammation.
Insulin resistance was more prevalent in nondiabetics
with infection-induced inflammation/oxidative stress
than type 2 diabetics, while the hyperbolic product
(insulin secretion × sensitivity) showed a similar and faster
deterioration than in Caucasian type 2 diabetics. Infected
nondiabetics with inflammation/oxidative stress occupied
an intermediate position between controls with normal
glucose tolerance without inflammation/oxidative stress
and those with type 2 diabetes mellitus and inflammation/
oxidative stress.
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